2023-12-25 18:37:59
This podcast is intended exclusively for healthcare professionals.
Our guest
Dr. Manuel Alejandro Márquez Martínez (@Kidney_Power), internist and nephrologist, graduated from the Salvador Zubirán National Nutrition Institute, assigned to the Department of Internal Medicine, Nephrology at Regional Hospital No. 6 in Tampico, Mexico.
Kidney Week
In early November 2023, Philadelphia became the epicenter of kidney medicine with the celebration of the Kidney Week 2023. This annual event brings together medical experts, researchers and healthcare professionals from around the world to explore the latest advances in the field of nephrology.
Since its founding in 1966, the American Society of Nephrology (ASN) has led the fight to prevent, treat and cure kidney diseases around the world. The American Society of Nephrology has played a crucial role in educating healthcare professionals and scientists, fostering research and innovation in nephrology, communicating new knowledge, and advocating for the highest quality of care for patients.
The American Society of Nephrology It has nearly 21,000 members from 140 countries, making it a global network of nephrology experts who share a common commitment: improving kidney health and patients’ quality of life.
DUPLEX: Esparsentan Versus Irbesartan in Patients With Segmental and Focal Glomerulosclerosis
The DUPLEX study, a multicenter, double-blind, placebo-controlled trial, compared esparsentan with irbesartan in patients aged 8 to 75 years with biopsy-confirmed focal segmental glomerulosclerosis. Participants were also required to have a urinary protein/creatinine ratio ≥1.5 g and an estimated glomerular filtration rate (eGFR) of at least 30 ml/min/1.73m². The primary objective was to reduce the loss in estimated glomerular filtration rate slope in the final analysis, and an interim analysis was performed at 36 weeks focused on the reduction in proteinuria.
371 patients were included in the study, divided equally between esparsentan and irbesartan. Regarding the primary objective, there were no significant differences between the groups in the change in the slope of the estimated glomerular filtration rate, with a difference of 0.3 ml/min/1.73m². However, at 36 weeks, 42.0% of patients treated with esparsentan achieved partial remission of proteinuria in focal and segmental glomerulosclerosis, compared with 26.0% of the irbesartan group (relative risk [RR]: 1.55; 95% confidence interval [IC 95%]: 1,1 a 2,18; p = 0,009)
REFERENCE
-
Rheault MN, Alpers CE, Barrat J, Bieler S, y cols.; DUPRO Steering Committee and DUPLEX Investigators. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. N Engl J Med. 3 Nov 2023. doi: 10.1056/NEJMoa2308550. PMID: 37921461. Fuente
1703538727
#Echoes #Kidney #Week